Inhibrx Biosciences Net Cash Flow 2023-2025 | INBX

Inhibrx Biosciences net cash flow from 2023 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Inhibrx Biosciences Net Cash Flow 2023-2025 | INBX

Inhibrx Biosciences net cash flow from 2023 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$245.4B
Amgen (AMGN)$157.5B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100B
Bristol Myers Squibb (BMY)$98.1B
CSL (CSLLY)$85.5B
GSK (GSK)$79.6B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$59.9B
Argenex SE (ARGX)$40.5B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26.9B
Royalty Pharma (RPRX)$20.9B
Biogen (BIIB)$19.9B
Incyte (INCY)$16.6B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
Moderna (MRNA)$10.9B
QIAGEN (QGEN)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.5B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.1B
Roivant Sciences (ROIV)$8B